/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

CalciMedica Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$4.7 0.0196(1.96%) CALC at 04 Dec 2025 04:27 PM Biotechnology
Lowest Today 4.23
Highest Today 4.725
Today’s Open 4.23
Prev. Close 4.6
52 Week High 4.82
52 Week Low 1.42
Day’s Range: Low 4.23 High 4.725
52-Week Range: Low 1.42 High 4.82
1 day return -
1 Week return +11.63
1 month return +58.24
3 month return +48.03
6 month return +150.0
1 year return +56.66
3 year return -
5 year return -
10 year return -

Institutional Holdings

Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 66.28 M

PB Ratio 6.9827

PE Ratio 0.0

Enterprise Value 56.34 M

Total Assets 19.79 M

Volume 39208

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-56575000 -56.6M, FY22:-35605000 -35.6M, FY21:-35821000 -35.8M, FY20:-27531000 -27.5M, FY19:-37037000 -37.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:-15000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-15000 -0.0M

Quarterly Net worth Q3/2025:-7804000 -7.8M, Q2/2025:-5956000 -6.0M, Q1/2025:-5042000 -5.0M, Q3/2024:-5618000 -5.6M, Q2/2024:-3954000 -4.0M

Fund house & investment objective

Company Information CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops Auxora for the treatment of acute ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory indications. The company is based in La Jolla, California.

Organisation Biotechnology

Employees 15

Industry Biotechnology

CEO Dr. A. Rachel Leheny Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow